AnaptysBio gains as GSK granted FDA label expansion for Jemperli

AnaptysBio (ANAB) rose after partner GSK (GSK) received FDA approval to expand Jemperli's label for treating certain rectal cancers. The drug is now approved for adults with stage II/III MSI-H/dMMR locally advanced rectal cancer, a subset of 5%-10% of rectal cancers. The approval came earlier than the expected February 2027 date.

Original reporting
Published Oct 19, 2026, 5:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 5:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AnaptysBio gains as GSK granted FDA label expansion for Jemperli — source image
Decision brief

The 30-second read

$ANABBullishHigh
01

Why it matters

Regulatory approval is a catalyst for biotech stocks, often triggering immediate price appreciation.

02

Market read

The news provides a fresh, material catalyst for ANAB and a secondary boost for GSK, offering a clear trading opportunity.

03

What to watch

Potential competition from other MSI‑H/dMMR therapies and reimbursement uncertainties.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

AnaptysBio (ANAB) partners with GSK on the anti‑PD‑1 therapy Jemperli. The FDA expanded its label to include stage II/III MSI‑H/dMMR rectal cancer.

Company-level read

Ticker impact

$ANABBullishHigh confidence
Context

FDA approved label expansion for Jemperli, boosting AnaptysBio's market prospects.

Expected impact

upward pressure as market prices in expanded indication.

Evidence & confidence

First report of FDA label expansion; biotech stocks typically rally on such approvals.

$GSKBullishMedium confidence
Context

GSK's partner drug Jemperli received FDA label expansion, enhancing GSK's oncology pipeline.

Expected impact

slight upward pressure as investors credit expanded sales opportunity.

Evidence & confidence

GSK benefits indirectly; impact less direct than for ANAB.

Market effects

Strengthens the oncology/immune‑oncology segment, may lift peer biotech valuations.

U.S. biotech market gains confidence from FDA approval.

Highlights continued pipeline growth for Western pharma partners.

Counterpoint

If the expanded indication yields limited uptake, the rally could be short‑lived.

Key entities

  • AnaptysBio

    Biotech firm developing Jemperli in partnership with GSK.

  • GlaxoSmithKline

    Pharma partner whose drug received the label expansion.

Related articles

$GSKMed

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working

GSK's Nelkarmi (neladalkib) received FDA accelerated approval for ALK-positive NSCLC patients after prior ALK therapy. Approval based on ALKOVE-1 trial showing 49% tumor shrinkage in Alecensa-only group. GSK acquired Nelkarmi via Nuvalent acquisition. Continued approval contingent on confirmatory trial. ALKAZAR phase 3 trial ongoing for first-line treatment.

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.